Clinical Research Details
Title:
RTOG 0418 A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-Operative Patients with Either Endometrial or Cervical Carcinoma
Purpose:
The purpose of this study is to determine the transportability of IMRT to a multi-institutional setting, and to test the hypothesis that there is a reduction in short-term bowel injury with this regimen compared to standard treatments. Adverse events related to this treatment regimen will be assessed. The rates of local regional control, distant metastasis, disease free and overall survival will be evaluated. Chemotherapy compliance with this regimen for the cervical carcinoma patients will observed.
Study Number:
109035
Number of Patients:
92
Elgibility:
Patients must have undergone a hysterectomy (total abdominal hysterectomy, vaginal hysterctomy or radical hysterectomy or laparoscopic assisted vaginal hysterectomy) for carcinoma of the cervix or endometrium seven weeks prior to study entry. Patients with endometrial carcinoma must also have had a bilateral salpingo-oophorectomy. Patients must require postoperative radiation therapy. Patients diagnosed with endometrial cancer must meet the specific pathology requirements.
Treatment:
Patients with endometrial and cervix cancer will get radiation therapy given once a day, five days a week for 28 days. If you have cervical cancer, you also will receive the chemotherapy drug cisplatin during radiation treatments. Five doses of cisplatin will be given starting at the time of radiation.
Principal Investigator:
Enrollment Phone:
(708) 216-2568